摘要
目的观察腔内应用奈达铂治疗恶性胸腔积液的疗效及安全性。方法本组72例，支气管肺癌46例，乳腺癌14例，食管癌12例。分治疗组和对照组，治疗组38例：奈达铂80～100mg／次，生理盐水40～50ml稀释；对照组34例：顺铂50～80mg／次，生理盐水40～50ml稀释。超声引导下胸腔注药，间歇5～7天1次，共计不超过3次。结果治疗组和对照组胸腔积液的完全缓解率分别为26．3％和20．6％，有效率分别为73．7％和64．7％，两组差异无统计学意义（P〉0．05）。全组患者腔内治疗的毒副反应轻微，均无气胸、胸腔感染、胸壁种植等严重并发症。结论奈达铂治疗恶性胸腔积液疗效显著，毒副作用轻，适合临床推广应用。
Objective To study the efficacy of nedaplatin （NDP） in the treatment of malignant hydrothorax. Methods There were 72 patients with malignant hydrothorax including 46 cases lung cancer, 14 cases breast cancer and 12 cases esophagogastric cancer, which were divided into 2 groups. One group of 38 patients was treated with NDP and the other group of 34 patients with DDP. NDP（80-100mg） diluted to 40-50ml with NS or DDP （50-80mg） with NS were respeetively injected into pleural cavity, and may be given less than three times at regular interval （about 5-7 days） by B ultrasound-guided and drained hydrothorax. Results The complete remission and response rates of NDP and DDP groups were 26. 3% ,20. 6% and 73.7% ,64. 7%. There were no significant difference between NDP and DDP groups in therapeutic effect （ P 〉0. 05 ）. There were light in toxic reactions and no pneumothorax, pleural infection,and no catheter fracture,infection and obstruction in NDP and DDP groups. Conclusion There is significant therapeutic effect of NDP in the treatment of malignant hydrothorax.
出处
《临床肿瘤学杂志》
CAS
2010年第7期649-651,共3页
Chinese Clinical Oncology
关键词
奈达铂
恶性胸腔积液
疗效
Nedaplatin
Malignant hydrothorax
Therapeutic effect
